Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma
NCT01082809
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
59
Enrollment
OTHER
Sponsor class
Conditions
Advanced Biliary Tract Adenocarcinoma
Interventions
DRUG:
Sunitinib
Sponsor
Samsung Medical Center